Clinical Report: Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

Overview

In a small randomized trial, all 16 patients receiving an individualized cancer vaccine remained disease-free after a median follow-up of 41 months, compared to three recurrences in the control group. The vaccine, TG4050, demonstrated immune responses and tolerability.

Background

Head and neck squamous cell carcinoma (HNSCC) is associated with a high risk of recurrence after surgery, particularly in HPV-negative cases. Current treatment options are limited. Personalized cancer vaccines, such as TG4050, represent a novel approach to harnessing the immune system against cancer-specific mutations.

Data Highlights

Key Findings

• All 16 patients in the TG4050 treatment group remained disease-free after a median follow-up of 41 months.
• Three of the 16 patients in the control group experienced disease recurrence.
• The vaccine induced detectable T-cell responses in 73.3% of evaluated patients.
• Responding patients recognized a median of three vaccine targets.
• No unexpected safety findings were reported during long-term follow-up.

Clinical Implications

Further studies are needed to confirm these results and evaluate the vaccine's efficacy in larger populations.

Conclusion

The results from this trial indicate that personalized cancer vaccines like TG4050 may improve disease-free survival in patients with head and neck cancer.

Related Resources & Content

1. Transgene and NEC, Nature Communications, 2026 -- A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial
2. The ASCO Post, 2024 -- Investigational Personalized Vaccine in Resected Head and Neck Cancers
3. The ASCO Post, 2023 -- Personalized mRNA Vaccines May Transform the Treatment of Melanoma
4. The Medicine Maker, 2026 -- Phase III Success Marks Milestone for Personalized Cancer Vaccines
5. FDA, 2025 -- FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma
6. the medicine maker — Phase III Success Marks Milestone for Personalized Cancer Vaccines
7. Frontiers in Oncology — Head and Neck Cancer Therapeutic Vaccines: A Review
8. https://www.oregon.gov/oha/HPA/DSI-HERC/MembersOnly/7.5f%20NCCN%201.2026%20head-and-neck.pdf
9. FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma | FDA
10. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer | New England Journal of Medicine
11. LPS WO40242 IMvoke010 Final Results September 2024 English
12. A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial | Nature Communications